Vallard A, Rancoule C, Le Floch H, Guy J-B, Espenel S, Le Péchoux C, Deutsch É, Magné N, Chargari C
Département de radiothérapie, institut de cancérologie Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France.
Service de pneumologie, hôpital d'instruction des armées Percy, 101, avenue Henri-Barbusse, 92140 Clamart, France.
Cancer Radiother. 2017 Aug;21(5):411-423. doi: 10.1016/j.canrad.2017.03.004. Epub 2017 Jun 5.
Radiation-induced lung injuries mainly include the (acute or sub-acute) radiation pneumonitis, the lung fibrosis and the bronchiolitis obliterans organizing pneumonia (BOOP). The present review aims at describing the diagnostic process, the current physiopathological knowledge, and the available (non dosimetric) preventive and curative treatments. Radiation-induced lung injury is a diagnosis of exclusion, since clinical, radiological, or biological pathognomonic evidences do not exist. Investigations should necessarily include a thoracic high resolution CT-scan and lung function tests with a diffusing capacity of the lung for carbon monoxide. No treatment ever really showed efficacy to prevent acute radiation-induced lung injury, or to treat radiation-induced lung fibrosis. The most promising drugs in order to prevent radiation-induced lung injury are amifostine, angiotensin-converting-enzyme inhibitors and pentoxifylline. Inhibitors of collagen synthesis are currently tested at a pre-clinical stage to limit the radiation-induced lung fibrosis. Regarding available treatments of radiation-induced pneumonitis, corticoids can be considered the cornerstone. However, no standardized program or guidelines concerning the initial dose and the gradual tapering have been scientifically established. Alternative treatments can be prescribed, based on clinical cases reporting on the efficacy of immunosuppressive drugs. Such data highlight the major role of the lung dosimetric protection in order to efficiently prevent radiation-induced lung injury.
放射性肺损伤主要包括(急性或亚急性)放射性肺炎、肺纤维化和闭塞性细支气管炎伴机化性肺炎(BOOP)。本综述旨在描述其诊断过程、当前的病理生理学知识以及现有的(非剂量测定方面的)预防和治疗方法。放射性肺损伤是一种排除性诊断,因为不存在临床、放射学或生物学方面的特征性证据。检查必须包括胸部高分辨率CT扫描和肺功能测试,其中肺一氧化碳弥散量是一项重要指标。尚无治疗方法真正显示出对预防急性放射性肺损伤或治疗放射性肺纤维化有效。预防放射性肺损伤最有前景的药物是氨磷汀、血管紧张素转换酶抑制剂和己酮可可碱。目前在临床前阶段正在测试胶原蛋白合成抑制剂,以限制放射性肺纤维化。关于放射性肺炎的现有治疗方法,皮质类固醇可被视为基石。然而,尚未科学地制定出关于初始剂量和逐渐减量的标准化方案或指南。可根据关于免疫抑制药物疗效的临床病例报告开出替代治疗方案。这些数据凸显了肺部剂量测定保护在有效预防放射性肺损伤方面的重要作用。